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Osteoarthritis	is	the	most	common	cause	of	arthritis	in	the	dog	and	affects	up	to	20	per	cent	
of	 the	 adult	 canine	 population.	 Other	 causes	 of	 arthritis	 include,	 for	 example,	 immune	
medicated	 and	 sepsis.	 In	 dogs	 both	 primary	 and	 secondary	 forms	 of	 osteoarthritis	 occur	
although	the	secondary	form	is	far	more	common.	This	form	occurs	following	injury	or	insult	
to	 the	 affected	 joint,	 for	 example,	 cranial	 cruciate	 ligament	 rupture,	 articular	 fracture	 or	
osteochondrosis,	which	initiates	the	biochemical	cascade	leading	to	a	common	pathway	of	
arthritis.	
	
The	susceptibility	of	any	individual	to	osteoarthritis	is	related	to	factors	such	as	genetics,	age	
and	systemic	factors	such	as	obesity.	Superimposed	on	this	inherent	susceptibility	are	local	
factors	 such	 as	 instability	 and	 injury	 to	 the	 joint	 itself.	 Models	 of	 osteoarthritis	 are	 well	
documented	in	the	literature	(Dieppe	and	Lohmander	2005)but	are	not	within	the	scope	of	
this	article.	
	
Clinically,	 the	 major	 presenting	 signs	 are	 lameness,	 stiffness,	 exercise	 intolerance	 or	 an	
unwillingness/inability	to	climb	or	jump.	The	signs	can	be	attributed	to	the	primary	inciting	
cause,	pain	associated	with	arthritis	or	a	combination	of	both.		
	
History	
	
It	is	important	to	start	with	an	accurate	and	complete	history	when	assessing	patients	with	
osteoarthritis.	 In	 dogs,	 osteoarthritis	 has	 specific	 breed	 and	 age	 predilections	 so	 the	
signalment	 of	 an	 animal	may	 help	 the	 clinician	 in	 reaching	 a	 diagnosis.	 For	 example,	 hip	
dysplasia	 is	 present	 in	 very	 young	 medium-	 to	 large-breed	 dogs	 and	 the	 secondary	
radiographic	changes	are	evident	from	a	very	early	age.	
	
More	specific	questions	that	need	to	be	asked	when	taking	a	history	include:	
• duration	of	lameness		
• clinical	progression	
• response	to	any	treatment		
• any	history	of	trauma	or	other	inciting	causes	
• behavioural	changes	
• response	to	amount	of	exercise	performed	
• effects	of	weather.	
	
The	most	common	manifestation	of	osteoarthritis	 is	 so-called	 ‘inactivity	stiffness’.	Owners	
report	 that	 their	 pet’s	 lameness	 seems	 to	 resolve	 during	 exercise	 but	 then	worsens	 after	
periods	 of	 rest	 following	 these	 bouts	 of	 activity.	 Other	 common	 presentations	 include	 a	
change	in	the	animal’s	ability	to	climb,	for	example,	the	stairs,	or	jump,	such	as	into	the	back	
of	the	car.	
	
As	 part	 of	 the	 history-taking	 and	 ongoing	management	 of	 osteoarthritis	 there	 have	 been	
recent	efforts	to	design	and	validate	client-based	questionnaires	that	provide	a	summative	
score	and	can	be	used	to	assess	the	severity	of	the	disease	at	the	outset	and	the	response	to	
any	treatment.	Although	these	questionnaires	have	not	been	fully	validated	they	provide	a	
useful	 tool	 in	 the	management	of	 osteoarthritis	 and	 are	 available	 either	 as	 downloads	or	
under	licence	(Brown	and	others	2008,	Walton	and	others	2013).	
	
Physical	examination	
	
Osteoarthritis	is	usually	secondary	to	a	primary	inciting	cause	so	a	diagnosis	of	osteoarthritis	
alone	is	usually	insufficient	and	the	clinician	needs	to	identify	the	primary	cause.	A	physical	
examination	 should	be	 systematic	and	complete.	 It	 is	useful	 to	 compare	 the	 contralateral	
limb	when	assessing	the	range	of	motion,	and	also	when	looking	for	soft	tissue	swelling	and	
muscle	 atrophy.	 However,	 since	 the	 most	 common	 forms	 of	 orthopaedic	 disease	 (eg,	
cruciate	disease,	elbow	dysplasia	and	hip	dysplasia)	can	frequently	present	bilaterally	this	is	
not	always	useful.	
	A	complete	analysis	of	 the	gait	 should	be	performed.	This	 is	most	commonly	done	 in	 two	
ways:	
• The	 patient	 can	 be	 examined	 while	 in	 the	 consultation	 room	 during	 the	
history	 taking.	 This	 can	 often	 reveal	 very	 subtle	 lameness	 and	 allows	 the	
clinician	 to	 monitor	 the	 animal	 lying	 down	 and	 standing	 up	 as	 well	 when	
walking	around	the	consultation	room.	
• Further	analysis	of	the	gait	should	be	made	in	an	area	that	allows	the	animal	
to	be	walked	and	 trotted	 in	 a	 straight	 line.	 The	animal	 should	be	observed	
walking	away	from	and	back	towards	the	clinician,	as	pelvic	limb	lameness	is	
often	more	 obvious	 when	 walking	 away	 and	 thoracic	 limb	 lameness	 when	
walking	back	towards	the	clinician.			
• This	 is	 usually	 performed	 before	 the	 physical	 examination	 as	 the	 lameness	
may	 be	 worsened	 by	 the	 examination,	 although	 repeated	 single	 joint	
examination	followed	by	immediate	gait	analysis	may	help	to	localise	lesions,	
especially	in	the	more	subtle	cases.	
	
Osteoarthritis	 is	 associated	with	 a	 variety	 of	 clinical	 and	 physical	 signs	 that	 are	 similar	 to	
many	joint	-related	conditions,	such	as			
• lameness	
• reluctance	to	exercise	
• inactivity	stiffness	
• pain	
• Joint	effusion	
• muscle	atrophy	
• joint	thickening	
• altered	range	of	motion	
• altered	gait	
• altered	behaviour.	
	
Assessing	 thickening	 and	 effusions	 in	 the	 hip	 and	 shoulder	 are	 not	 possible	 due	 to	 the	
presence	of	the	overlying	muscle	masses.	Assessment	of	the	range	of	motion	should	be	both	
to	assess	any	reduction	in	the	normal	planes	of	motion	for	a	joint,	for	example,	flexion	and	
extension,	but	also	to	assess	abnormal	increases	in	range	of	motion	such	as	the	cranial	draw	
test	 for	 cruciate	 ligament	 disease.	 It	 is	 often	 better	 to	 perform	 these	 latter	 tests	 under	
sedation	as	they	can	be	painful	for	the	patient	and	difficult	to	interpret	in	conscious	animals	
	
After	 finishing	a	 complete	history	and	physical	 examination	 the	 clinician	will	 often	have	a	
good	idea	of	potential	differential	diagnoses	and	a	plan	can	be	formulated	based	on	this.	
	
Further	investigations	
	
Haematology	and	biochemistry	are	not	routinely	taken	in	cases	of	osteoarthritis	unless	the	
history	and	physical	findings	indicate	a	reason	to	do	so.	Blood	tests	may	be	useful	in	older	
animals	or	where	long-term	medical	therapy	is	planned.	
	
Radiography	 is	 the	 mainstay	 in	 clinical	 practice	 for	 diagnosis	 of	 osteoarthritis	 in	 dogs.	
However,	 its	 limitations	 must	 be	 appreciated	 as	 it	 mainly	 provides	 information	 on	 the	
osseous	changes,	such	as	sclerosis	and	osteophyte	formation,	providing	a	limited	amount	of	
information	about	 the	 soft	 tissues.	Radiographic	 signs	of	 osteoarthritis	 are	 relatively	non-
specific	and	include:	
• osteophytosis	
• enthesiophytosis	
• subchondral	sclerosis		
• effusion	
• soft	tissue	swelling	
• intra-articular	mineralisation	
• cysts.	
	
Although	 the	 presence	 of	 osteophytes	 can	 be	 used	 to	 diagnose	 osteoarthritis,	 there	 is	 a	
tendency	for	clinicians	is	to	focus	on	these	osseous	changes	even	if	they	do	not	necessarily	
correlate	 well	 to	 severity	 of	 disease	 or	 the	 clinical	 situation	 seen.	 Elbow	 dysplasia,	 for	
example,	produces	osteophytes	very	slowly	whereas	within	three	or	four	weeks	of	a	cranial	
cruciate	 ligament	 rupture	 there	will	be	 radiographic	evidence	of	osteoarthritis.	 It	has	also	
been	 shown	 that	 some	breeds	produce	more	osteophytes	 than	others	despite	having	 the	
same	degree	of	hip	laxity	(Smith	and	others	1995).	For	this	reason,	it	is	important	to	always	
evaluate	the	radiographs	in	line	with	the	clinical	situation	in	order	to	appropriately	manage	
the	cases.	
	
Subchondral	 sclerosis	 is	 commonly	 quoted	 as	 an	 indicator	 of	 osteoarthritis	 although	 its	
sensitivity	on	plain	radiography	is	limited,	due	to	the	wide	variation	in	exposure	factors	that	
can	 lead	 to	 apparent	 differences	 in	 density,	 and,	 in	 one	 study,	 detection	 of	 subchondral	
sclerosis	was	unacceptably	low	among	board-certified	radiologists	(Innes	and	others	2004).	
Care	 should	 be	 taken	 to	 not	 overinterpret	 this	 radiographic	 finding	 because,	 taken	 in	
isolation,	 it	 is	not	a	 reliable	 indicator	of	osteoarthritis.	However,	 if	 present	 in	 conjunction	
with	other	radiographic	findings,	it	can	be	used	to	confirm	the	diagnosis.	
	
Synovial	fluid	analysis	is	an	underused	diagnostic	test	in	clinical	practice.	With	osteoarthritis	
there	are	early	changes	that	occur	in	the	synovial	fluid	.	In	osteoarthritic	joints	the	volume	
of	 fluid	may	 be	 increased,	 cell	 counts	 (predominantly	monocytes	 (>88%)	 are	 usually	 low	
(less	 than	 5x	 109	WBC/l)	 and	 can	 often	 be	within	 normal	 limits	 (<2	 x109	WBC/l),	 and	 the	
colour	 remains	 clear	 to	 pale	 yellow.	 In	 the	 early	 stages	 of	 the	 disease	 viscosity	 is	 not	
reduced	although,	as	the	hyaluronic	acid	concentration	diminishes	over	time,	the	viscosity	
decreases.	 Hydroxyapatite	 crystals	 are	 common	 features	 in	 the	 synovial	 fluid	 of	 human	
patients	with	OA	but	laboratories	do	not	routinely	them	and	the	significance	with	respect	to	
clinical	outcome	and	treaments	in	dogs	is	unknown.		The	authors	do	not	request	HA	counts	
from	their	labs	on	submitted	samples.	Biomarkers	have	been	investigated	as	a	possible	way	
of	 diagnosing	 osteoarthritis	 and	 although	 several	 potential	markers	 have	 been	 identified,	
none	are	validated	in	the	dog.	
	
Advanced	imaging	modalities	such	as	MRI	and	CT	are	becoming	more	routinely	available	to	
clinicians	 and,	 therefore,	 their	 use	 is	 increasing	 in	 the	work-up	 of	 orthopaedic	 cases.	 For	
patients	with	osteoarthritis,	CT	can	be	useful	in	the	early	stages	of	disease,	as	it	may	help	to	
identify	 the	 primary	 lesion	 which	may	 not	 be	 present	 or	 obvious	 on	 radiographs.	 This	 is	
particularly	 the	 case	 for	 elbow	 dysplasia,	 where	 the	 primary	 medial	 coronoid	 disease	 is	
often	 not	 visible	 on	 radiographs	 and	 progression	 of	 osteoarthritis	 may	 be	 so	 slow	 that	
radiographs	appear	normal	when	taken.	CT	is	also	much	more	useful	than	radiography	when	
investigating	complex	joints	such	as	the	elbow,	carpus	and	tarsus.	
	
MRI	 can	be	useful	 as	 it	 gives	 better	 information	 about	 the	 articular	 soft	 tissue	 structures	
such	as	ligaments,	menisci	and	the	synovium.	The	main	disadvantage	of	MRI,	apart	from	its	
expense,	is	that	canine	cartilage	is	very	thin	and	most	of	the	magnets	available	to	veterinary	
surgeons	are	not	powerful	enough	to	have	a	sufficient	signal-to-noise	ratio	to	allow	accurate	
detection	of	cartilage	lesions.	
	
Scintigraphy	 is	 very	 limited	 in	 its	 availability	 due	 to	 the	 restrictions	 governing	 the	 use	 of	
radioactive	 material.	 Its	 relative	 lack	 of	 usefulness	 clinically	 also	 limits	 its	 use.	 As	 it	 can	
readily	 identify	 areas	 of	 increased	 bone	 turnover,	 it	 is	 most	 commonly	 used	 in	 cases	 of	
occult	lameness	where	the	source	of	the	lameness	is	not	obvious.		
	
Arthroscopy	 Although	 mainly	 considered	 to	 be	 a	 surgical	 tool,	 arthroscopy	 also	 has	 a	
diagnostic	 application	 and,	 given	 its	 ever-increasing	 availability,	 now	 offers	 the	 best	 and	
most	 cost-effective	 method	 for	 staging	 osteoarthritis	 in	 dogs	 (see	 surgical	 management	
section	below).		Depending	upon	the	joint	involved	arthroscopic	surgery	may	involve:	
	
• joint	 debridement	 and	 micropicking	 of	 the	 subchondral	 bone	 (to	 release	
mesenchymal	stem	cells)	
• assessment	of	the	cartilage	surfaces	through	observation	and	palpation	
• Removal	of	loose	fragments/	lesions	to	facilitate	fibrocartilage	formation	
• Surgical	techniques	to	stabilise	the	joint.	
		
	
Management	of	osteoarthritis	
The	 management	 of	 osteoarthritis	 may	 involve	 a	 combination	 of	 medical	 and	 surgical	
approaches.	Owners	need	to	be	counselled	from	the	outset	that	osteoarthhritis	 is	 likely	to	
be	a	lifelong	process	with	flare-ups	that	may	increase	in	severity	and	frequency	as	the	dog	
ages.	The	approach	to	these	cases	often	involves	a	balancing	act	between	exercise,	medical	
management,	weight	management	(if	the	dog	is	overweight),	and	surgery.	
	
Exercise	
Although	 one	 study	 demonstrated	 that	 a	 short	 period	 of	 exercise	 (1.2	 km	 of	 trotting)	
increased	the	degree	of	lameness	when	measured	on	a	force	platform	(Beraud	and	others	
2010),	very	little	is	really	known	about	the	effects	of	exercise	on	osteoarthritis.	In	people	it	
does	 seem	 that	 some	exercise	may	be	beneficial	 and	 certainly	 in	 canine	patients	exercise	
should	 be	 moderated	 but	 continued.	 Anecdotally,	 no	 exercise	 may	 be	 as	 detrimental	 as	
doing	 extremes	 of	 exercise.	 When	 advising	 owners	 on	 exercise	 levels	 for	 their	 dog	 it	 is	
important	to	advise	them	to	try	and	avoid	exuberant	activities	such	as	chasing	balls,	agility	
activities	 or	 other	 forms	 of	 high-energy	 exercise.	 When	 a	 flare-up	 of	 osteoarthritis	 has	
occurred	 for	most	patients	 the	best	course	of	action	 is	 to	 reduce	 the	 levels	of	exercise	 to	
short	 frequent	 lead	walks	which,	 if	 appropriate,	 are	 gradually	 increased	 over	 a	 period	 of	
weeks	to	previous	levels	of	exercise.	
	
Medical	management	
Drugs	that	are	used	to	manage	osteoarthritis	can	be	divided	into	two	main	categories:	
• symptom-modifying		
• structure-modifying.	
	
Symptom-modifying:	The	main	drugs	 that	 can	modify	 clinical	 signs	 are	 aimed	at	 relieving	
the	pain	associated	with	osteoarthritis,	include:	
• NSAIDs	
• paracetamol/codeine	(Pardale	V;	Dechra)	
• oral	opioids	(egbuprenorphine,	tramadol)		
• gabapentin	
• amantadine	
• corticosteroids.	
	
It	 is	 important	 for	clinicians’	 to	abide	by	the	Cascade	system	when	prescribing	medication	
for	 the	management	 of	 osteoarthritis	 and	 not	 just	 go	 for	 the	more	 ‘fashionable’	 options.	
Most	 cases	 of	 osteoarthritis,	 especially	 in	 the	 early	 stages,	 can	more	 than	 adequately	 be	
managed	with	 a	 balanced	 approach	 using	 licensed	medication	 in	 combination	with	 other	
treatment	modalities,	in	particular,	weight	control.	
	
Non-steroidal	anti-inflammatory	drugs	(NSAIDs)	
These	form	the	backbone	of	the	medical	options	for	the	management	of	osteoarthritis	and	
an	ever	 increasing	range	of	 licensed	products	 is	available	 for	dogs	(Fig	1).	NSAIDs	work	by	
inhibiting	 the	 cyclooxygenase	 (COX)	 enzyme	 in	 order	 to	 reduce	 prostaglandin	 production.	
Two	main	forms	of	COX	exist,	namely	COX	1	(constitutive)	and	COX	2	(inducible),	although	
this	 classification	 is	 somewhat	 simplified	 and	 cross	 over	 between	 the	 functions	 of	 the	
classes	exist.	A	third	class,	COX	3,	has	been	identified	and	may	be	the	target	for	paracetamol	
(acetaminophen).	COX	3	is	found	in	greatest	abundance	in	the	canine	brain	and	paracetamol	
has	a	greater	ability	to	cross	the	blood	brain	barrier	better	than	other	NSAIDs	so	offers	an	
alternative	 pathway	 for	 pain	 managment.	 Note,	 paracetamol	 is	 not	 considered	 to	 be	 a	
NSAID	as	it	has	only	weak	anti-inflammatory	activity.	
	
NSAIDs	have	been	developed	to	be	more	selective	for	COX	2	in	preference	to	COX	1	in	order	
to	 allow	 analgesia	 to	 occur	 without	 creating	 the	 common	 side	 effects	 (in	 particular	
gastrointestinal	 irritation	 and	 ulceration,	 nausea,	 diarrhoea	 and	 renal	 papillary	
necrosis)associated	with	inhibiting	COX	1.	A	drug	that	selectively	induces	COX	2	inhibition	at	
a	concentration	lower	than	that	needed	to	inhibit	COX	1	is	potentially	safer	although	this	is	
an	 oversimplification	 of	 the	 actual	 situation.	 There	 is	 not	 a	 clear	 distinction	 between	 the	
pathways	of	constitutive	and	inducible	prostaglandins	and,	in	some	cases,	Cox	2	provides	a	
protective	effect	(e.g.	in	inflamed	gastrointestinal	mucosa)	.	However	drugs	(e.g	meloxicam	
and	carprofen)	 that	provide	analgesia	without	 significant	 inhibition	of	Cox	1	pathways	 (so	
called	Cox	2	selective)	have	been	shown	to	have	greater	safety	profiles.			
	
	
Osteoarthritis	is	a	long-term	disease	and	management	should	be	aimed	at	the	chronic	pain	
associated	with	it	and	not	just	the	acute	flare-up.	Many	(table	1)	(can	this	data	be	put	into	a	
table??)	of	the	drugs	currently	available	are	licensed	for	use	for	more	than	28	days,	which	
allows	 the	 clinician	 to	 prescribe	 long-term	 therapies	 although	 it	 is	 prudent	 to	 reduce	 the	
levels	to	the	lowest	effective	dose	(which	may	be	below	that	stated	in	the	data	sheets),	with	
a	 return	 to	higher	doses	 in	 cases	of	 flare-ups.	 It	 should	also	be	noted	 that	 the	efficacy	of	
NSAIDs	in	individual	patients	can	be	very	variable	and	the	lack	of	response	to	one	particular	
NSAID	should	not	be	see	as	a	lack	of	response	to	NSAIDs	per	se.	If	a	change	in	NSAID	is	to	be	
trialled	then	a	few	days	gap	(washout)	should	be	left	to	reduce	the	risks	of	side	effects.		It	
may	be	necessary	during	that	period	to	use	alternative	analgesia	protocols	to	manage	the	
pain.	 The	 licensing	 laws	 require	 drugs	 in	 the	 same	 class	 to	 show	 efficacy	 equivalent	 to	
current	licensed	products	as	well	as	equal	safety	so	the	newer	products	are	not	necessarily	
more	efficacious.	
	
Paracetamol/codeine	
Paracetamol/codeine	(Pardale	V;	Dechra)	is	 licensed	in	dogs	for	use	in	the	management	of	
pain	but	only	for	five	days	and	not	in	conjunction	with	NSAIDs.	Its	use	in	the	management	of	
osteoarthritis,	 within	 the	 license,	 is	 therefore	 limited.	 However,	 in	 the	 human	 field	
paracetamol	 is	 now	 routinely	 used	 in	 conjunction	with	NSAIDs	 as	 an	 alternating	 protocol	
and	we	use	similar	protocols	in	our	practice,	albeit	off	license.	The	licensed	dose	for	Pardale	
V	 is	 one	 tablet	 per	 12.5kg/	 twice	 daily	 which	 equates	 to	 33.33	 mg/kg	 of	 paracetamol.	
Paracetamol	alone	is	not	licensed	but	the	recommended	dose	rate	is	10	mg/kg	twice	daily.		
If	Pardale	V	is	used	in	conjunction	with	NSAID	the	authors	use	it	at	a	dose	rate	of	10mg/kg	
which	equates	to	one	tablet	per	40kg	twice	daily.		Pardale	V	may	be	useful	in	cases	where	
NSAID	 intolerance	 has	 been	 reported	 or	 in	 cases	 where	 patients	 are	 already	 on	 steroid	
therapy	for	another	reason.	The	course	can	be	extended	for	longer	than	five	days	but	this	is	
again	an	off	license	indication.	Paracetamol	should	never	be	used	in	cats	due	to	potentially	
fatal	toxicity.		
	
Oral	opiates/tramadol	
Tramadol	 is	 anecdotally	 reported	 to	 be	 a	 popular	 therapy	 given	 by	 veterinary	 surgeons	
although	there	is	little	evidence	of	its	efficacy	and	the	drug	is	not	licensed	for	use	in	dogs	or	
cats	in	the	UK.	It	has	recently	been	reclassified	as	a	Schedule	3	controlled	drug.	Tramadol	is	
metabolised	into	eight	substrates	of	which	only	one	is	active	in	the	dog,	and	that	is	only	for	
a	short	(one	to	two	hours)	period.	If	tramadol	is	used	then	careful	monitoring	of	the	patient	
is	 needed	 to	 ensure	 adequate	 levels	 of	 analgesia	 are	 provided	 (Benitez	 and	 others	 2015,	
Delgado	and	others	2014).		
 	
Gabapentin	and	amantadine	
Gabapentin	 and	 amantadine	 are	 drugs	 that	 are	 designed	 to	manage	 chronic	 pain	 but	 are	
unlicensed.	Amantadine	works	by	acting	on	the	N-methyl-D-aspartate	(NMDA)	receptor	and	
reduces	 the	 prolonged	 inflammatory	 pain	 associated	 with	 chronic	 disease.	 One	 study	 of	
dogs	 showed	an	 improvement	 in	 terms	of	both	 veterinary-	 and	owner-assessed	 lameness	
when	 used	 with	 meloxicam	 compared	 to	 those	 case	 on	 meloxicam	 only;	 by	 day	 42,	 the	
amantadine	and	meloxicam	group	had	improved	scores	(Lascelles	and	others	2008)	.	
	
Gabapentin	 works	 on	 the	 g-aminobutyric	 acid	 (GABA)	 receptor	 and	 is	 thought	 to	 reduce	
neuropathic	pain,	although	its	exact	mechanism	is	not	known.	The	use	of	these	drugs	should	
not	be	routine	and	each	case	where	this	is	being	considered	needs	to	be	carefully	judged.	
In	 the	 authors	 clinic	 they	 are	 generally	 used	 in	 those	 cases	 that	 are	 refractory	 to	 a	
multimodal	management	of	pain	in	chronic	cases	of	OA.	
	
Corticosteriods	
The	 use	 of	 these	 drugs	 in	 the	 management	 of	 osteoarthritis	 is	 generally	 restricted	 to	
isolated	 joints	 where	 a	 long	 acting	 	 intraarticular	 injection	 (of	 methylprednisolone	
acetate)may	provide	rapid	alleviation	of	clinical	signs	without	inducing	systemic	signs.		The	
response,	although	rapid	and	significant	,	is	often	only	relatively	short	lived	and	often	needs	
repeating	once	or	twice.	Multiple	repeats	in	excess	of	this	are	not	recommended	due	to	the	
detrimental	effects	of	the	steroid	on	the	articular	cartilage.		Systemic	steroid	therapy	should	
be	avoided	due	to	the	potential	side	effects	of	the	medication.	
	
	Structure	modifying	drugs	
	
Structure-modifying	drugs	are	 less	 available	 for	 dogs	 due	 to	 the	 strict	 criteria	 needed	 to	
validate	 such	 drugs.	 The	 main	 example	 includes	 pentosan	 polysulphate	 (Cartrophen;	
Biopharm	Australia),	which	is	a	licensed	product	made	from	beech	and	similar	in	structure	
to	heparin.	Clinical	 trials	of	 this	drug	have	shown	mixed	 results	and	 two	systemic	 reviews	
have	concluded	that	only	a	moderate	level	of	comfort	is	achieved	when	using	this	product	
for	canine	osteoarthritis	(Aragon	and	others	2007,	Sanderson	and	others	2009)		
	
Nutritional	management	of	osteoarthritis	
A	 lot	 of	 effort	 has	 gone	 into	 the	 development	 of	 nutritional	 means	 of	 managing	
osteoarthritis	 recently	 and	 an	 ever-increasing	 number	 of	 nutraceutical	 products	 are	
available	to	the	clinician.	However,	the	majority	of	these	show	only	anecdotal	evidence	of	
efficacy	with	little	evidence	to	support	their	claims.	As	opposed	to	pharmaceutical	products,	
which	 are	 under	 the	 direct	 regulation	 of	 the	 Veterinary	 Medicines	 Directorate	 (VMD)	
through	the	Veterinary	Medicines	Regulations	2006,	nutraceuticals	are	not	subjected	to	the	
same	restrictions	unless	they	make	specific	health	claims.	The	definition	of	what	constitutes	
a	 health	 claim	 is	 quite	 vague	 but	 essentially	 any	 claim	 relating	 to	 a	 specific	 disease,	 as	
opposed	 to	 maintaining	 a	 healthy	 body	 system	 would	 require	 the	 relevant	 marketing	
authority.	If	no	such	claims	are	made	then	regulation	lies	with	the	Food	Standards	Agency.	
The	regulations	are	mainly	limited	to	the	composition	and	labelling	of	the	product	but	also	
cover	food	hygiene	controls	during	the	manufacturing	process.	
In	vitro	work	into	glucosamine	has	shown	that	it	can	alter	chondrocyte	metabolism	and	this	
is	 the	 rationale	 for	 its	 use	 in	 osteoarthritis.	 However,	 the	 efficacy	 of	 glucosamine	 in	 vivo	
remains	 unproven	 and	 evidence	 is	 lacking	 as	 to	 whether	 oral	 glucosamine	 reaches	 the	
chondrocytes	in	any	useful	form.	Similar	findings	have	been	seen	with	chondroitin	sulphate	
where	there	has	been	much	debate	over	whether	the	molecule	reaches	articular	cartilage	
intact	or	as	a	depolymerised	version.The	benefits	of	nutraceuticals	 in	 the	management	of	
osteoarthritis	 are	 debatable	 and	 two	 large	 double-blinded	 negative-controlled	 studies	
reported	 no	 significant	 efficacy	 (Clegg	 and	 others	 2006,	 Moreau	 and	 others	 2003)	 and	
current	evidence	remains	insufficient	to	endorse	their	efficacy	in	the	management	of	canine	
osteoarthritis.	
	
Essential	 fatty	 acids,	 in	 particular	 omega	 3,	 have	 been	 shown	 to	 affect	 synovial	 fluid	
metalloproteinase	 and	 tissue	 inhibitors	 of	 metalloproteinase	 concentrations	 following	
surgery	 for	 rupture	 of	 the	 cranial	 cruciate	 ligament	 (Hansen	 and	 others	 2008)	 .	 Further	
studies	 using	 objective	 outcome	 measures	 showed	 significantly	 increased	 levels	 of	 peak	
vertical	 force	 in	 dogs	 with	 osteoarthritis	 fed	 the	 test	 food	 diet	 compared	 to	 the	 control	
group	(Fritsch	and	others	2010,	Roush	and	others	2010).	This	improvement	was	seen	in	82	
per	cent	of	the	test	food	group	compared	to	38	per	cent	of	the	controls.		
	
Weight	management	
Obesity	 is	 one	 of	 the	 most	 important	 medical	 diseases	 in	 dogs,	 with	 recent	 studies	
suggesting	that	approximately	half	of	all	pet	dogs	are	either	overweight	(≥10%	above	ideal	
weight)	or	obese	(≥20%	above	ideal	weight)	(German	2006).		Overweight	dogs	often	have	a	
number	of	health	concerns	and	an	increased	risk	of	developing	other	diseases,	most	notably	
orthopaedic	disease.	In	addition,	a	recent	study	(German	et	al	2012)	has	also	demonstrated	
that	various	aspects	of	quality	of	life	are	worse	in	obese	dogs,	as	they	tend	to	be	less	mobile	
and	more	 likely	 to	 show	 signs	 of	 chronic	 pain	 than	dogs	with	 an	 ideal	weight.	 Therefore,	
weight	 control	 can	 be	 a	 useful	 adjunct	 therapy	 for	 overweight	 dogs	 with	 concurrent	
osteoarthritis.	 Indeed,	 recent	 studies	 (Mlacknik	 et	 al	 2006;	 Marshall	 et	 al	 2010)	 have	
demonstrated	 that	 weight	 loss	 can	 significantly	 improve	 the	 gait	 of	 obese	 osteoarthritic	
dogs,	 as	 judged	 by	 force-plate	 analysis.	 There	 is	 also	 evidence	 of	 improved	 quality	 of	 life	
when	 obese	 dogs	 lose	 weight,	 and	 this	 includes	 significant	 improvements	 in	 activity	 and	
evidence	 of	 a	 decrease	 in	 chronic	 pain.	 So,	 while	 the	 evidence	 for	 many	 therapeutic	
measures	(including	nutritional	modification)	have	not	been	well	established,	the	benefits	of	
weight	loss	are	clear.	It	is	worth	emphasising	that	the	benefits	of	increased	mobility	can	be	
demonstrated	 with	 only	 a	 modest	 amount	 of	 weight	 loss;	 improvements	 in	 gait	 can	 be	
observed	on	force-plate	analysis	once	body	weight	 loss	exceeds	6	per	cent	 (Marshall	et	al	
2010).	 Such	 a	 degree	of	weight	 loss	 can	be	 achieved	within	 two	 to	 three	months,	 and	 at	
least	80	per	cent	of	dogs	will	be	successful	with	such	a	programme	(Deagle	et	al	2014).	
	
Weight	management	strategies	
In	the	last	10	years,	two	microsomal	membrane	transfer	protein	inhibitor	drugs	(dirlotapide	
and	mitratapide)	have	been	available,	which	were	licensed	(as	Slentrol;	Pfizer	and	Yarvitan;	
Janssen)	 for	 controlled	 weight	 loss	 in	 overweight	 dogs.	 While	 the	 reported	 efficacy	 in	
published	studies	was	good	(Gossellin	et	al	2007;	Pena	et	al	2014),	performance	in	clinical	
practice	was	more	disappointing,	and	they	failed	to	gain	widespread	acceptance.	In	light	of	
this,	 both	 drugs	 have	 been	 withdrawn	 from	 the	 market.	 Therefore,	 the	 most	 widely	
accepted	 strategy	 for	 weight	 management	 continues	 to	 be	 dietary	 energy	 restriction	 in	
conjunction	with	increasing	physical	activity.	
	
Use	of	weight	management	should	always	be	considered	in	conjunction	with	other	forms	of	
medical	management	 and	 surgery.	 The	 sooner	 a	weight	management	 protocol	 is	 started,	
the	sooner	 the	benefits	will	be	observed.	That	said,	because	 the	process	can	 take	 time,	 it	
should	 not	 be	 used	 as	 the	 sole	 strategy,	 as	 other	medical	 therapies	 can	 alleviate	 clinical	
signs	 sooner.	 Indeed,	 combining	 weight	 management	 with	 other	 strategies	 might	
improvement	 outcomes;	 for	 example,	 if	 analgesia	 alleviates	 chronic	 pain,	mobility	 can	 be	
improved	and	this	might	help	to	promote	weight	loss.	The	timing	of	weight	management	in	
relation	to	surgery	should	also	be	considered.	Successful	surgery	can	improve	mobility	and	
again	may	 improve	 the	 outcomes	 of	 weight	 loss;	 however,	 delaying	 surgery	 until	 after	 a	
period	of	weight	loss	may	reduce	the	risks	of	complications	of	the	procedure.	It	might	also	
be	 that,	 as	 mobility	 improves,	 the	 need	 for	 surgery	 deceases.	 As	 a	 general	 guide	 for	 an	
overweight	dog	with	concurrent	osteoarthritis,	we	would	suggest	a	short	period	of	weight	
management	(two	to	three	months)	before	any	surgical	procedure,	provided	that	this	delay	
is	 appropriate.	 Such	a	period	 is	 a	 reasonable	 compromise	 since,	 as	mentioned	above,	 the	
vast	majority	of	dogs	will	successfully	lose	weight	and	measurable	improvements	in	mobility	
will	be	expected.	
	
Dietary	management	
Purpose-formulated	weight	loss	diets	(do	you	want	to	give	any	egs	here?)	should	always	be	
used	 because	 they	 tend	 to	 be	 supplemented	 in	 essential	 nutrients	 relative	 to	 energy	
content,	 which	 reduces	 the	 chance	 of	 malnutrition	 arising.	 These	 diets	 are	 often	
supplemented	with	protein	and	fibre,	which	is	known	to	minimise	signs	of	hunger	in	the	pet	
thereby	improving	owner	compliance.	Food	intake	during	weight	loss	should	be	accurately	
measured,	with	 the	 exact	 amount	 fed	 depending	 upon	 the	 food	 used,	 the	 dog’s	 sex	 and	
whether	 it	 is	 neutered.	 A	 recent	 study	 has	 also	 demonstrated	 that	 obese	 dogs	 with	
orthopaedic	disease	need	a	greater	level	of	energy	restriction	to	achieve	successful	weight	
loss	than	dogs	that	are	not	lame	(German	et	al	2014).	It	is	critical	for	the	owner	to	measure	
food	portions	precisely	 (eg,	using	electronic	scales),	because	other	methods	(including	the	
use	 of	 measuring	 cups)	 are	 unreliable	 and	 usually	 lead	 to	 overfeeding.	 Table	 scraps	 and	
treats	 should	be	 avoided,	 although	 some	 treats	 (especially	 those	with	 a	purported	health	
benefit	 such	as	a	dental	 chew)	can	be	allowed,	provided	 that	 the	energy	content	 is	 taken	
into	 account	within	 the	 feeding	 strategy.	A	 final	 consideration	 is	 how	 the	 food	 should	be	
fed.	Rather	than	using	feeding	bowls,	puzzle	feeders	are	a	good	idea,	and	these	can	either	
be	hollow	toys	or	modified	 feed	bowls.	The	devices	have	been	shown	to	slow	feed	 intake	
dramatically,	 which	 can	 help	 to	 reduce	 hunger	 and	 improve	 enjoyment	 of	 the	 feeding	
process.	
	
Lifestyle	management	
In	addition	to	dietary	management,	increasing	physical	activity	can	help	with	the	weight	loss	
programme.	 Owners	 often	 struggle	 with	 weight	 management	 programme	 for	 their	 pet	
because	of	the	strength	of	the	owner-pet	bond,	and	the	fact	that	they	are	deprived	of	the	
main	method	 they	use	 to	demonstrate	 love	 to	 their	 pet.	 Strategies	 that	 increase	physical	
activity	can	provide	an	alternative	means	 for	an	owner	to	 interact	with	their	pet.	There	 is	
also	emerging	evidence	that	including	such	strategies	into	weight	management	programmes	
might	 improve	the	outcomes	(Chauvet	et	al	2011).	Suitable	strategies	 include	regular	 lead	
walking,	 hydrotherapy	 (such	 as	 the	 use	 of	 underwater	 treadmills	 and	 swimming),	 and	
various	methods	of	increasing	play	activity,	including	the	use	of	puzzle	feeders.	Not	only	do	
the	latter	slow	food	intake,	but	the	can	also	increase	play	activity	and	mental	stimulation.	
	
Monitoring	the	weight	management	regime	
To	maximise	the	chance	of	success,	the	weight	management	regime	needs	to	be	monitored	
closely,	usually	by	performing	regular	weight	checks.	At	the	start,	most	clinicians	choose	to	
undertake	 such	 checks	 every	 two	 weeks,	 but	 the	 interval	 can	 be	 altered	 if	 consistent	
progress	is	made,	and	it	better	suits	the	owner.	The	same	set	of	electronic	scales	should	be	
used	to	ensure	consistency.	Body	weight	checks	should	be	continued	periodically	after	the	
target	weight	has	been	reached	(e.g.	at	2	weeks,	4	weeks,	and	3	months,	and	then	at	least	
twice	a	year	thereafter),	in	order	to	reduce	the	likelihood	of	rebound	weight	gain	occurring.		
Continuing	to	feed	the	weight	management	diet,	during	the	maintenance	period,	makes	the	
likelihood	of	rebound	less	likely	(German	et	al	2012b).	
	
Surgical	management	of	osteoarthritis	
Most	patients	with	osteoarthritis	can	be	managed	with	a	combination	of	medical	measures	
and	 other	 conservative	 measures.	 However,	 for	 some	 patients	 and	 some	 joints,	 the	
response	 is	 poor	 and	 surgical	 management	 should	 be	 considered.	 Although	 arthroscopic	
management	 is	 relatively	 routine	 for	people	with	osteoarthritis,	 there	 is	 little	evidence	 to	
support	it	in	the	management	of	canine	osteoarthritis	and	so	is	not	recommended.	
	
The	mainstay	of	the	canine	surgical	management	of	osteoarthritis	is	total	joint	arthroplasty.	
Joint	 replacements	 are	 readily	 available	 for	 the	 hip,	 stifle	 and	 elbow	 although	 bespoke	
replacements	have	been	performed	 in	other	 joints.	Of	 these,	 the	 total	hip	 replacement	 is	
currently	 the	 most	 commonly	 performed	 and	 most	 reliable	 arthroplasty,	 with	 good	 to	
excellent	 function	being	achieved	 in	more	than	90	per	cent	of	cases	 (Allen	2012)	 .	Such	 is	
the	 success	of	 this	procedure	 that	 intervention	 is	now	performed	at	 a	much	earlier	 stage	
than	 previously	 recommended.	 Dogs	 in	 their	 early	 adult	 years	 with	 pain	 associated	 with	
osteoarthritis	 that	 is	 affecting	quality	of	 life	may	well	 undergo	a	 total	 hip	 replacement	as	
this	may	allow	these	animals	to	lead	normal,	and	in	some	cases	full	working,	lives.	Stifle	and	
elbow	replacements	are	technically	more	challenging	and	remain	salvage	procedures	where	
all	else	has	failed.	
	
In	 some	 cases,	 total	 joint	 replacement	 is	 not	 possible	 and	 arthrodesis	may	 be	 a	 suitable	
alternative.	This	has	the	effect	of	removing	the	intractable	pain	although	it	produces	a	rigid	
joint	and	so	is	better	suited	to	the	low	motion	joints	such	as	the	carpus	and	tarsus.	Elbow,	
stifle	 and	 shoulder	 arthrodesis	 is	 possible	 and	 tolerated	 reasonably	well	 but	 is	 technically	
challenging.	Arthrodesis	of	the	coxofemoral	joint	is	not	possible,	and	so	a	femoral	head	and	
neck	excision	should	be	performed	if	replacement	is	not	possible.	
	
In	extreme	cases	amputation	is	a	possibility,	although	in	most	cases	patients	have	multi-limb	
osteoarthritis	so	careful	preoperative	assessment	is	essential	to	ensure	the	patient	will	still	
be	able	to	ambulate	following	surgery.	Euthanasia	is	an	option	in	some	extreme	cases	where	
the	 welfare	 of	 the	 animal	 is	 a	 concern	 and	 treatment	 options	 have	 failed	 or	 are	 not	
affordable.	
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Table	1	–list	of	the	licensed	NSAID	products	currently	available.			
	
	
	
	
	 	
Drug generic 
name 
Trade name Licensed formulation Species 
Meloxicam 
  
  
Meloxidyl 5mg/ml injection Dogs/cats 
Meloxidyl 1.5mg/ml suspension Dogs  
Meloxidyl 0.5mg/ml Cats 
Metacam Chewable tablets 1 or 2.5mg Dogs  
Metacam  5mg/ml solution  Dogs/cats 
Metacam  1.5mg/ml suspension Dogs  
Metacam  0.5mg/ml suspension  Cats  
RevitaCAM 5mg/ml oromucosal spray  Dogs  
Inflacam 1.5mg/ml oral suspension  Dogs  
Inlflacam 1 and 2.5mg chewable tablets Dogs  
Meloxivet 0.5 and 1.5mg/ml oral 
suspension  
Dogs 
    
Carprofen Carprodyl 10, 20 or 100mg tablets Dogs  
Rimadyl 50mg/ml solution  Dog/cat  
Dolagid 50mg tablet and 120mg 
chewable tablet  
Dogs  
    
Phenylbutazone Phenylbutazone 200mg tablets Dogs 
    
Mavacoxib Trocoxil 6, 20, 30, 75 or 95mg 
chewable tablets 
Dogs  
    
Cimicoxib Cimalgex 8, 30, 80mg chewable tablets Dogs  
    
 Tolfedine 6, 20 and 60mg tablets Dogs/cats  
    
Chinchophen PLT 200mg (plus 1mg 
prednisolone) 
Dogs  
    
Robenacoxib Onsior 6mg flavoured tablets Cats 
Onsior 5, 10, 20 and 40mg flavoured 
tablets 
Dogs 
Onsior 20mg/ml solution  Dogs/cats 
    
Firocoxib Previcox 57 and 227mg chewable 
tablets 
Dogs  
    
Ketoprofen Ketofen 5, 20mg tablets Dogs 
Ketofen 1% solution  Dogs 
    
Tolfenamic acid  Tolfedine  4% injection Dogs/cats  
Tolfedine 6, 20, 60 mg tablets  Dogs/cats  
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